Mark Mallon wraps a short stint as CEO of Ironwood, jumping out to pursue 'multiple passions' in the wake of setbacks

John Carroll

Editor & Founder

Mark Mallon built his career over a 24-year stretch at AstraZeneca. But he managed less than 2 years as CEO of Ironwood.

Ironwood announced Monday afternoon that Mallon is stepping down, quoting him as enthused about the chance to satisfy “multiple passions” as he headed off in pursuit of a new leadership post. The biotech’s stock was up 13% ahead of the bell Tuesday.

President Tom McCourt was bumped to the interim CEO role during the recruitment phase for the next CEO and the board chair, Julie McHugh, will help steer the company as executive chairman.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Mark Mallon wraps a short stint as CEO of Ironwood, jumping out to pursue 'multiple passions' in the wake of setbacks

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Mark Mal­lon wraps a short stint as CEO of Iron­wood, jump­ing out to pur­sue 'mul­ti­ple pas­sion­s' in the wake of set­backs

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Mark Mallon wraps a short stint as CEO of Ironwood, jumping out to pursue 'multiple passions' in the wake of setbacks

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir